Medical Oncologist
Your report explained
Residual cancer burden (RCB) after neoadjuvant chemotherapy
Residual cancer burden measures how much cancer was left in the breast and lymph nodes after chemotherapy given before surgery. It is worked out from the tissue removed at your operation. The less that is left, the better the cancer responded. This page explains each class and, just as importantly, what the result cannot tell you.
MM
Medically reviewed by Dr. Muralidhar MuddusettyConsultant Surgical Oncologist · MBBS (AIIMS), MS (Surgery, AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh) · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
The short answer
What does residual cancer burden mean?
Residual cancer burden, written as RCB, measures how much cancer was left in the breast and lymph nodes after chemotherapy given before surgery. It is worked out from the surgical specimen. The less that is left, the better the cancer responded.
Why it is measured at all
When chemotherapy is given before surgery, the operation becomes a direct test of whether the treatment worked. Nothing else in breast cancer gives that answer so plainly. RCB turns what the pathologist sees into a single graded result your team can act on.
How the grades run
The scale runs from no cancer found at all, through small and moderate amounts, to extensive disease remaining. Your report will name a class rather than a percentage. The classes are read alongside your subtype, because the same class means different things in different subtypes.
Not every centre reports RCB. Some describe the response in words instead. Both are valid ways of saying the same thing.On your report
The classes, in plain language
- RCB-0
- No invasive cancer found in the breast or the nodes. This is the same thing as a complete response, often written as pCR.
- RCB-I
- A small amount of cancer remains. Outcomes in this group are generally close to those for a complete response.
- RCB-II
- A moderate amount remains. This is the most common result and covers a wide range within it.
- RCB-III
- Extensive cancer remains. It usually prompts a discussion about additional treatment after surgery.
- pCR, or pathological complete response
- No invasive cancer left. DCIS may still be present and the result is still counted as complete.
- Neoadjuvant
- Treatment given before surgery. Adjuvant means the same treatment given after.
Not sure whether this applies to you?
Ask an oncologistWhat it changes
What your RCB result actually decides
This is one of the few results that directly changes what is offered to you after surgery.
Whether more treatment is added
Where cancer remains, particularly in triple negative or HER2 positive disease, an additional treatment after surgery is often offered specifically because of that.
It means different things by subtype
A moderate amount left in a hormone sensitive cancer is common and expected, because these cancers respond slowly to chemotherapy. The same result in a triple negative cancer carries more weight.
Always ask what your class means for your subtype.It guides how closely you are followed
A higher class usually means closer follow-up in the first years, and a lower threshold for investigating a new symptom.
It may open a trial
Several clinical trials recruit specifically from people with cancer remaining after neoadjuvant chemotherapy. Ask whether any are open to you before treatment after surgery is finalised.
Worth asking
- What class am I, and why
- What does that add to my treatment
- Is a trial open for this result
Talk to our team
Have a question about your situation?
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Side by side
The same class, read differently by subtype
Your subtype
How the result is usually read
Triple negative
A complete response is strongly reassuring; anything left usually prompts extra treatment
HER2 positive
Complete responses are common; cancer remaining generally changes the treatment given afterwards
Hormone sensitive, HER2 negative
Complete responses are uncommon and their absence is not alarming; hormone tablets do the long work
Any subtype, extensive disease remaining
Prompts a full review of the plan and a discussion about trials
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Being straight with you
What RCB cannot tell you
RCB describes what was found on one day, in the tissue that was removed. It is a strong guide to how your cancer behaved under chemotherapy. It is not a forecast of your life.
A good result is not a promise
A complete response is genuinely encouraging and is associated with better outcomes. It does not mean the cancer cannot return, which is why treatment continues afterwards for many people. Anyone presenting it as the end of the story is overselling it. What it tells your team is that this cancer was sensitive to the drugs it was given, which is useful information if it ever needs treating again.
A poor result is not a verdict
Families read RCB-III as a sentence. It is a reason to add treatment, and additional treatments for exactly this situation now exist that did not a decade ago. It changes the plan rather than closing it.
Hormone sensitive cancers are different
These cancers often shrink slowly and rarely disappear completely on chemotherapy. A moderate class in this group is an ordinary result, not a failure, and the long-term work is done by hormone tablets over years rather than by the chemotherapy that preceded surgery.
What to do with the result
Write your class down and keep the report. Ask your oncologist three things: what class you are, what is being added to your treatment because of it, and what would have been offered had the result been different. Those answers turn a letter and a number into something you can actually act on.
Commonly believed
What families assume about this result
Cancer left behind means the chemotherapy failed.
Shrinking a tumour substantially is a real response, even when it is not a complete one. In hormone sensitive cancers a partial response is the usual outcome. Failure would mean growth during treatment, and that is a different finding your team would have acted on at the time.
A complete response means treatment can stop.
It does not. Radiotherapy, HER2 treatment or hormone tablets usually continue as planned. The complete response tells you the cancer was sensitive to what was given; finishing the plan is what keeps that advantage.
We should have gone straight to surgery instead.
Giving chemotherapy first often allows a smaller operation, and it produces this information, which surgery first cannot. Knowing how the cancer responded is what makes additional treatment possible for those who need it.
My RCB number can be compared with someone else's.
Not usefully. The same class means different things in different subtypes, and a great deal depends on what treatment follows. Comparing your class with a relative's or a stranger's online tells you almost nothing.
Questions we are asked
Common questions about residual cancer burden
Is RCB-0 the same as being free of cancer?
It means no invasive cancer was found in the tissue that was removed and examined. That is a very good result and it is the one everyone hopes for. It is not the same as a promise that no cell survived anywhere, which is why treatment continues as planned.
My report does not mention RCB. Should it?
Not every laboratory reports it. Many describe the response in words, naming how much tumour remained and whether the nodes cleared. Ask your oncologist to translate what your report says into a response category if that helps you understand it.
Does DCIS left behind count against the result?
No. A complete response is defined by the absence of invasive cancer. DCIS, which is cancer still held inside the ducts, may remain and the result still counts as complete. Your surgeon will still want it removed with a clear margin.
Will I get extra treatment because cancer was left?
Quite possibly, and that is one of the main reasons the result is measured. What is added depends on your subtype. Ask directly what is being recommended because of this result and what would have been offered without it.
Why did my tumour not respond as well as expected?
Response depends mostly on the biology of the cancer rather than on anything you did or did not do. Hormone sensitive cancers in particular respond slowly to chemotherapy. It is not caused by diet, by stress or by a missed cycle.
Can RCB be worked out from a scan instead?
No. Scans during treatment show whether the tumour is shrinking, which is useful, but they cannot see microscopic disease. Only the removed tissue read under a microscope can give this result, which is why it comes after surgery.
Should I ask for a second opinion on the result?
It is reasonable where the class sits at a boundary and extra treatment turns on it. Ask the hospital in writing for the blocks and slides. A review of the tissue is far more useful than a second reading of the typed report.
Does a good response mean I can avoid radiotherapy?
Usually not. Radiotherapy is decided on what the cancer was at the start and on the operation performed, rather than on the response to chemotherapy. Your radiation oncologist will explain which areas are being treated and why.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Where to find us
Our centres in and around Hyderabad
Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.
Warangal
Vizag
Talk to our team
Speak to a breast cancer specialist
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Sources
- Cancer Research UK — Chemotherapy before surgery for breast cancer
- National Cancer Institute — Pathologic complete response
- Breast Cancer Now — Chemotherapy before surgery
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.